A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM ... the G7 and Libre 3 range. Analysts at William Blair said that with two devices ...

One of the largest healthcare companies in India, Abbott sells a wide range of products, including medicines, nutrition, ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

The Omnipod 5 automated insulin delivery system now works with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor, Insulet announced this week. Adding compatibility for the 15-day CGM may ...

Against the backdrop of aging, chronic diseases, and a growing population, the healthcare system is going through a vital transformation. Healthcare is simply becoming increasingly individual-centric.